论文部分内容阅读
左旋咪唑(Levamisole 简称LMS)是一种广泛应用的驱虫药。动物实验及临床证明,在化疗中LMS 有利于骨髓的恢复。直至目前尚未见应用左旋咪唑治疗再生障碍性贫血(简称再障)的报道。丰田等曾报告11例再障,其中8例的AE—玫瑰花结低下,7例的淋巴细胞转化率降低,提示再障患者外周血T 细胞中存在生物活性异常的亚群。也有报道LMS 可使血红蛋白(简称Hb)显著增高。我院于1978年10月开始试用左旋咪唑治疗再障40例,现将单一应用LMS 治疗10例及原来应用中药的基础上加用本药者2例,对其近期疗效作一分析。
Levamisole (LMS) is a widely used anthelmintic. Animal experiments and clinical evidence, LMS in chemotherapy is conducive to the recovery of bone marrow. Until now there is no application of levamisole treatment of aplastic anemia (referred to as aplastic anemia) reported. Toyota had reported 11 cases of aplastic anemia, including 8 cases of low AE-rosette, 7 cases of lymphocyte transformation rate decreased, suggesting that aplastic anemia in patients with peripheral blood T cells in the presence of abnormal biological subpopulation. It has also been reported that LMS can significantly increase hemoglobin (referred to as Hb). In our hospital in October 1978 trial of levamisole treatment of aplastic anemia in 40 cases, now a single application of LMS treatment in 10 cases and the original application of traditional Chinese medicine on the basis of plus the drug in 2 cases, an analysis of its immediate effect.